In pristane-induced lupus mice, injection of tofacitinib, a Janus kinase (JAK) 1/JAK3 inhibitor, significantly inhibited the expression of suppressor of cytokine signaling (SOCS) 1 but upregulated the expression of SOCS3 (27). This evidence concerns the gene JAK3 and systemic lupus erythematosus.